Health-related quality of life in people with type 2 diabetes participating in the LEADER trial

Journal article


Publication Details

Author(s): Nauck MA, Buse JB, Mann J, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A
Journal: Diabetes Obesity & Metabolism
Publication year: 2019
Volume: 21
Journal issue: 3
Pages range: 525-532
ISSN: 1462-8902


Abstract

Aims To assess health-related quality of life (HRQoL) in people with type 2 diabetes (T2D) participating in the LEADER cardiovascular outcomes trial using the five-dimension European Quality of Life questionnaire (EQ-5D). Materials and methods The EQ-5D was administered every 12 months in a subset of patients from Canada, Denmark, Germany, Ireland, Italy, Netherlands, Spain, Sweden, the United Kingdom and the United States. We compared changes in utility index scores and visual analogue scale (VAS) scores from baseline to 36 months in participants treated with liraglutide and placebo. We also assessed which complications had the greatest impact on quality of life. Results At 36 months, less deterioration in EQ-5D utility index score was seen in the liraglutide group (-0.058) than in the placebo group (-0.082; estimated treatment difference [ETD] 0.023, 95% confidence interval [CI] 0.004;0.043; P = 0.020). A smaller decrease in EQ-5D VAS score was also demonstrated in the liraglutide group (-3.51) vs. the placebo group (-5.45; ETD 1.94, 95% CI 0.32;3.57; P = 0.019). The benefits of liraglutide treatment compared with placebo were driven primarily by shifts in the domains of mobility and self-care. The most influential events contributing to poorer HRQoL were stroke, heart failure, malignant neoplasm and confirmed hypoglycaemia. Conclusions Liraglutide demonstrated a modest but significant benefit in patient-reported health status using the EQ-5D, compared with placebo. This benefit may be of clinical relevance and requires further study.


External institutions
London School of Hygiene and Tropical Medicine
Novo Nordisk A/S
Ruhr-Universität Bochum (RUB)
University of North Carolina at Chapel Hill
University of Oxford


How to cite

APA:
Nauck, M.A., Buse, J.B., Mann, J., Pocock, S., Bosch-Traberg, H., Frimer-Larsen, H.,... Gray, A. (2019). Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes Obesity & Metabolism, 21(3), 525-532. https://dx.doi.org/10.1111/dom.13547

MLA:
Nauck, Michael A., et al. "Health-related quality of life in people with type 2 diabetes participating in the LEADER trial." Diabetes Obesity & Metabolism 21.3 (2019): 525-532.

BibTeX: 

Last updated on 2019-27-02 at 13:23